Chemical mechanism of the radiation potentiating effects of 2,2-dimethylaziridine-type antitumor agents.

@article{Bardos1979ChemicalMO,
  title={Chemical mechanism of the radiation potentiating effects of 2,2-dimethylaziridine-type antitumor agents.},
  author={Thomas J. Bardos and Joseph A. Dunn and Michael E. Perlman},
  journal={International journal of radiation oncology, biology, physics},
  year={1979},
  volume={5 9},
  pages={
          1653-6
        }
}
5 Citations
Radiation potentiating effect of ethyl bis(2,2-dimethyl-1-aziridinyl) phosphinate (AB-163).
A pilot study with ethyl bis (2,2-dimethyl-1-aziridinyl) phosphinate (AB-163) and radiation therapy.
Synthesis of Bis(Aziridinyl) Phosphinic Amide Derivatives of Thymidine as Potential Anticancer Agents
TLDR
The aziridine-containing compounds were tested for their cytotoxic action in vitro against the L1210 leukemia; the 3′-bis(aziridinyl)phosphinic amide derivative was found to be about 11-times more active than its 5′-counterpart in inhibiting the replication of these leukemic cells.
Phase I study of ethylbis(2,2-dimethyl-1-aziridinyl)phosphinate (AB-163)
TLDR
Ethylbis(2,2-dimethyl-1-aziridinyl)phosphinate (AB-163) was used to treat 27 patients in a phase I trial and one partial response in a patient with squamous-cell carcinoma of the cervix metastatic to the lungs was seen.

References

SHOWING 1-6 OF 6 REFERENCES
Radiation potentiating effect of ethyl bis(2,2-dimethyl-1-aziridinyl) phosphinate (AB-163).
Combination of chemotherapy with dual antagonists and radiotherapy in the treatment of neoplastic disease
TLDR
The theoretical justification for combination chemotherapy and for the combination of radiation and chemotherapy in the treatment of neoplastic diseases is discussed, and studies on the radiation‐potentiating effect of certain members of this group of drugs are reviewed, and prospects for therapeutic applications are discussed.
Radiation sensitizing agents in clinical radiation and chemotherapy.
Patients with bronchogenic carcinoma or with advanced pediatric solid tumours were treated with various radiation therapy schedules alone or with a new alkylating carbamate: AB 132. Drug therapy